CELZ (Creative Medical Technology) Company Net Income

CELZ (Creative Medical Technology) - company brandmark

The net balance of Creative Medical Technology (CELZ) demonstrates profit dynamics, where -0.01 records a new level mark. The development of the cellular portfolio is progressing organically through research alliances with institutes. The business relies on MedTech solutions for tissue regeneration and spinal treatment. However, extreme competition for biomedical patents creates serious risks of losing market prospects.

CELZ: Creative Medical Technology Holdings, Inc. Company Net Income 07/04/2022 - 10/29/2026

Financial and market metric breakdowns for creativemedicaltechnology.com (CELZ)

- price and consensus price forecast:
Stock Quotes Creative Medical Technology Holdings|CELZ - Analyst Consensus Forecast
- business market valuation indicators:
Market Value Creative Medical Technology|CELZ - Total Company Value
- balance sheet equity data:
Net Assets per Single Share Creative Medical Technology|CELZ - Company Book Value|Market Value to Book Value Ratio creativemedicaltechnology.com|CELZ - Aggregate Company Assets
- debt and liquidity details:
Total Debt to Capital Coefficient Creative Medical Technology|CELZ - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio Creative Medical Technology Holdings|CELZ - Company Debts|Debt to Net Assets Ratio Creative Medical Technology|CELZ - Company Long-Term Debts|Short-Term Debt Creative Medical Technology|Quick Ratio creativemedicaltechnology.com
- earnings and valuation multiples information:
CELZ - Net Income
Basic company analysis:Creative Medical Technology Holdings Inc. (CELZ)
Mass-produced product of Creative Medical Technology Holdings, Inc.

Creative Medical Technology (CELZ) profit represents the final financial result of operations net of all operating and tax expenses, reflecting the actual efficiency of cash generation. By analyzing the company's net income, an investor can see the impact of Creative Medical Technology (CELZ) exclusive regenerative treatment methods on margins, where the potential for monopoly pricing power in stem cell therapy directly drives the upward trend of this fundamental indicator.

Direct competitors

Net Income Mesoblast Pharma|LCTX (Lineage Cell Therapeutics) - Net Profit|Company Net Income surrozen.com SRZN|Company Net Income Cryo-Cell International (CCEL)|Company Net Income FBLG (fibrobiologics.com)|Company Net Income Longeveron Corp LGVN|BioRestorative Therapies Inc - Company Net Income